Resources

November 4, 2021

Webinar: Studying the Responses to Cytokines Using Novel In Vitro Stem Cell Platforms

Many promising new drugs fail human clinical trials due to a lack of efficacy or unanticipated toxicity. More predictive non-clinical models that reprise human physiology and accurately evaluate drug pharmacokinetics and safety are urgently needed. Building on organ-on-a-chip technology, researchers developed an intestine-on-a-chip that recapitulates the human gut. In this webinar, Bill Thelin, Ph.D, Chief Scientific Officer, Altis Biosystems discusses how intestine-on-a chip technology reliably models gastrointestinal disease and assists researchers in screening for safe, effective therapeutic candidates.    

August 5, 2021

The Power Of RepliGut® In Vitro Intestinal Stem Cell Models

Both current in vitro and in vivo models used in the development of candidate therapies for the treatment of intestinal diseases have severe limitations. RepliGut®, an in vitro human intestinal epithelial stem cell model, addresses many of these issues and has significant potential to reduce the time and cost of drug development. This model may even help to identify optimal therapies for individual patients.

April 12, 2021

Developing A Robust In Vitro Intestinal Model for Preclinical Candidate Screening of GI Toxicity

Gastrointestinal (GI) issues are common side effects of many drugs. Anticipating such side effects before clinical trials is limited by a lack of effective models for evaluating preclinical candidates for their potential to cause diarrhea, nausea, and other gut-related side effects. With its RepliGut® in vitro human intestinal model, Altis Biosystems is developing a system that could help pharma companies identify GI toxicity issues early in the drug development process.

March 11, 2021

Accurately Recapitulating Environmental Niches in In Vitro Models of the Intestine

Advanced microphysiological systems can replicate aspects of intestinal complexity, such as epithelium self-renewal by stem cells in in vitro crypts or the interactions of microbes and intestinal epithelium mediated by a mucus layer. Availability of such models is key to progress in compound screening, disease modeling, and microbiome research.

March 2, 2021

A Gut Feeling About the Future of Healthcare

Scott Magness, Chief Scientific Advisor at Altis Biosystems, discusses the impact that RepliGut®—a human stem cell-derived platform that recreates the intestinal epithelium—may have on stem cell research and drug testing. Watch previous video.